What is the current Price Target for the Inmune Bio, Inc. stock?

The average Inmune Bio, Inc. target price is $8.16. This is 322.80% higher than the current stock price. The highest price target is 389.64%, the lowest is 266.32%. 5 Analysts have issued a price target Inmune Bio, Inc. 2027 .

How high will the Inmune Bio, Inc. stock rise?

No reliable answer can be given as to how high the Inmune Bio, Inc. stock will rise. The performance of stocks, including the Inmune Bio, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Inmune Bio, Inc. stock today?

The performance of Inmune Bio, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Inmune Bio, Inc. stock fall?

The decline in Inmune Bio, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Inmune Bio, Inc. Forecast, price target & analysts

$1.92

0.78%

Nasdaq, Oct 05, 01:14 pm EDT. Market open.

ISIN

US45782T1051

Symbol

INMB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Analysts Charts Ownership News Strategies

Inmune Bio, Inc. Target price 2026 - Analyst rating & recommendation

Inmune Bio, Inc. Classifications & Recommendation

Buy

90%

Hold

10%

Inmune Bio, Inc. Price Target

Target Price	$8.16
Price	$1.93
Potential	322.80% register free of charge
Number of Estimates	5

	5 Analysts have issued a price target Inmune Bio, Inc. 2027 . The average Inmune Bio, Inc. target price is $8.16. This is 322.80% register free of charge higher than the current stock price. The highest price target is $9.45 389.64% register free of charge , the lowest is $7.07 266.32% register free of charge .
	A rating was issued by 10 analysts: 9 Analysts recommend Inmune Bio, Inc. to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Inmune Bio, Inc. stock has an average upside potential 2027 of 322.80% register free of charge . Most analysts recommend the Inmune Bio, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '25	2026 Estimates
Earnings Per Share $	-1.86	-0.56
	11.85%	69.89%
P/E		negative

6 Analysts have issued a Inmune Bio, Inc. forecast for earnings per share. The average Inmune Bio, Inc. EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2025. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2025	$-1.86	11.85%
2026	$-0.56 69.89% unlock
2027	$-0.79 41.07% unlock
2028	$-0.80 1.27% unlock
2029	$0.70 187.50% unlock
2030	$1.85 164.29% unlock
2031	$3.57 92.97% unlock
2032	$4.86 36.13% unlock
2033	$5.76 18.52% unlock

Current	-2.80	229.81%
2026	-3.44 22.98% unlock
2027	-2.46 28.49% unlock
2028	-2.43 1.22% unlock
2029	2.74 212.76% unlock
2030	1.05 61.68% unlock
2031	0.54 48.57% unlock
2032	0.40 25.93% unlock
2033	0.33 17.50% unlock

Inmune Bio, Inc....

Current Inmune Bio, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
LUCID CAPITAL MARKETS	Locked ➜ Locked	Locked	Mar 11 2026
Maxim Group	Locked ➜ Locked	Locked	Jul 02 2025
BTIG	Locked ➜ Locked	Locked	Jul 01 2025
Scotiabank	Locked ➜ Locked	Locked	Jul 01 2025
Maxim Group	Locked ➜ Locked	Locked	Feb 13 2025
Scotiabank	Locked ➜ Locked	Locked	Feb 11 2025
Alliance Global Partners	Locked ➜ Locked	Locked	Oct 21 2024

Analyst Rating	Date
Locked LUCID CAPITAL MARKETS: Locked ➜ Locked	Mar 11 2026
Locked Maxim Group: Locked ➜ Locked	Jul 02 2025
Locked BTIG: Locked ➜ Locked	Jul 01 2025
Locked Scotiabank: Locked ➜ Locked	Jul 01 2025
Locked Maxim Group: Locked ➜ Locked	Feb 13 2025
Locked Scotiabank: Locked ➜ Locked	Feb 11 2025
Locked Alliance Global Partners: Locked ➜ Locked	Oct 21 2024

Discover more stocks with a high price target

NIO ADR 86.90%

Alibaba Group Holding Ltd 80.17%

Rheinmetall 66.50%

Tencent Holdings Ltd. 60.60%

Adyen 56.10%

Uber Technologies 51.26%

BYD 49.89%

TUI 46.72%

Infineon 45.44%

Siemens Energy 43.75%

Netflix 43.74%

Adidas 43.36%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now